Apimeds Pharmaceuticals US, Inc. (APUS) stock forecast & analysis
7.89
NYSE American · USD
Up: +2.85, +56.5%
1 analysis
- Open
- 6.99
- Previous close
- 5.04
- Day range
- 7.48 – 8.80
- 52-week range
- 1.51 – 59.70
- Volume (shares)
- 17.47M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.51M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- Not available
- Market cap
- 11.91M
Market Scanner’s AI analysis of Apimeds Pharmaceuticals US, Inc. (APUS), updated September 2026: IndiGo's large aircraft order for Honeywell Aerospace avionics and APUs drove recent APUS coverage, alongside significant net losses and a volatile stock price.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Apimeds Pharmaceuticals US, Inc. (APUS) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
IndiGo's large aircraft order for Honeywell Aerospace avionics and APUs drove recent APUS coverage, alongside significant net losses and a volatile stock price.
Recent analyses for APUS covered a substantial order from IndiGo for Honeywell Aerospace avionics and APUs, indicating potential demand growth. The company, a specialty and generic drug manufacturer, has experienced significant net losses in recent periods, with operating income also showing large negative figures. Market data indicated a strong short-term uptrend in the stock price, with the RSI approaching overbought territory and MFI showing very strong buying pressure, despite a long-term downtrend indicated by the 200-day SMA.
APUS news & sentiment
News headlines highlighted a substantial aircraft avionics and APU order for the company, suggesting a positive development. General market sentiment appeared favorable, with mentions of 'Top Midday Gainers' potentially benefiting the company.
APUS technical picture
The stock price showed a medium-term uptrend, trading above its 50-day SMA and 10-day EMA, though remaining below its 200-day SMA. Momentum readings approached overbought territory, with strong buying pressure indicated, while MACD suggested weakening bearish momentum.
Fundamentals
The company has experienced significant net losses in recent periods, with operating income also showing large negative figures. Shareholder equity shifted from a deficit to a positive position, with total assets exceeding total liabilities.
Factors discussed — upside
- IndiGo selected Honeywell Aerospace avionics and APUs for 810 new Airbus aircraft.
- Stock price showing medium-term uptrend with 7-day change of +194.6%.
- RSI approaching overbought territory (66.11).
- Money Flow Index (MFI) at an extreme 99.66, indicating very strong buying pressure.
- Shareholder equity recovered to a positive $153,347,827 by December 31, 2025.
Factors discussed — risks
- Significant net losses in recent fiscal years and quarters.
- Operating income showing large negative figures in recent quarters.
- Stock price remains 61.6% below its 200-day SMA, suggesting a long-term downtrend.
- Shareholder equity was negative as of December 31, 2024.
- Aircraft orders
- Financial performance
- Stock price trends
- Market sentiment
Summary updated .
APUS technical indicators
Common technical indicators for APUS, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 4.20 | Price above |
| 10-day exponential moving average | 3.54 | Price above |
| Relative strength index (14-day) | 79.31 | Overbought |
| MACD line (12/26/9) | -0.0388 | Above its signal line |
| Bollinger bands (20-day, 2σ) | -0.18 – 5.69 | Price above the upper band |
Analyses
Recent APUS.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Apimeds Pharmaceuticals US, Inc.?
- The bull case for APUS centers on a substantial aircraft order from IndiGo for Honeywell Aerospace avionics and APUs, signaling potential demand growth. This is supported by recent stock price performance showing a medium-term uptrend and strong buying pressure indicated by market indicators.
- What are the risks for Apimeds Pharmaceuticals US, Inc.?
- Risks for APUS include significant net losses and negative operating income in recent periods, alongside a long-term stock price downtrend. Although shareholder equity has recovered, past negative equity and current financial performance present headwinds.
- Is Apimeds Pharmaceuticals US, Inc. bullish or bearish?
- Recent AI analyses of Apimeds Pharmaceuticals US, Inc. examined factors on both sides. Discussed upside: The bull case for APUS centers on a substantial aircraft order from IndiGo for Honeywell Aerospace avionics and APUs, signaling potential demand growth. This is supported by recent stock price performance showing a medium-term uptrend and strong buying pressure indicated by market indicators. Discussed risks: Risks for APUS include significant net losses and negative operating income in recent periods, alongside a long-term stock price downtrend. Although shareholder equity has recovered, past negative equity and current financial performance present headwinds. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Apimeds Pharmaceuticals US, Inc.?
- News headlines highlighted a substantial aircraft avionics and APU order for the company, suggesting a positive development. General market sentiment appeared favorable, with mentions of 'Top Midday Gainers' potentially benefiting the company.
- How does Market Scanner analyse Apimeds Pharmaceuticals US, Inc.?
- Every analysis of Apimeds Pharmaceuticals US, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh APUS.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.